Assante, Gabriella
Chandrasekaran, Sriram
Ng, Stanley
Tourna, Aikaterini
Chung, Carolina H.
Isse, Kowsar A.
Banks, Jasmine L.
Soffientini, Ugo
Filippi, Celine
Dhawan, Anil
Liu, Mo
Rozen, Steven G.
Hoare, Matthew
Campbell, Peter
Ballard, J. William O.
Turner, Nigel
Morris, Margaret J.
Chokshi, Shilpa
Youngson, Neil A.
Funding for this research was provided by:
foundation for liver research
australian research council (DP190102555)
singapore ministry of health via the duke-nus signature research programmes (MOH-000032/MOH-CIRG18may-0004)
Camille and Henry Dreyfus Foundation
National Institute of Health (R35 GM13779501)
CRUK-OHSU Project Award ((C52489/A29681))
CRUK Accelerator award to the HUNTER consortium ((C18873/A26813).)
Article History
Received: 10 August 2021
Accepted: 16 June 2022
First Online: 23 June 2022
Change Date: 18 May 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://0-doi-org.brum.beds.ac.uk/10.1186/s13073-023-01190-7
Declarations
:
: All rodent experiments were approved by the University of New South Wales Animal Care and Ethics Committee (Project numbers ACEC 11/82B and 13/55B).All human research conformed to the principles of the Helsinki Declaration. Whole genome sequence data for mutation burden comparisons and mutational signature extraction was done on samples as approved by the Cambridge University Hospitals NHS Foundation Trust (16/NI/0196). All biological samples were collected with informed consent from Addenbrooke’s Hospital, Cambridge, UK. The human liver samples used for ChIP and quantitative PCR were from human livers which had been rejected for transplantation acquired through the King’s College Hospital, London. The ethics approval for hepatocyte biology research came from the King’s Healthcare NHS Trust (LREC protocol 1998–0249) which covered the use of these samples in the current study.
: Not applicable.
: The authors declare that they have no competing interests.